CA3220929A1 - Fused tetracyclic compound, preparation method therefor and application thereof in medicine - Google Patents
Fused tetracyclic compound, preparation method therefor and application thereof in medicine Download PDFInfo
- Publication number
- CA3220929A1 CA3220929A1 CA3220929A CA3220929A CA3220929A1 CA 3220929 A1 CA3220929 A1 CA 3220929A1 CA 3220929 A CA3220929 A CA 3220929A CA 3220929 A CA3220929 A CA 3220929A CA 3220929 A1 CA3220929 A1 CA 3220929A1
- Authority
- CA
- Canada
- Prior art keywords
- omom
- boc
- fluoro
- hexahydro
- methanonaphtho
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110687643 | 2021-06-21 | ||
| CN202110687643.8 | 2021-06-21 | ||
| CN202110880105 | 2021-08-02 | ||
| CN202110880105.0 | 2021-08-02 | ||
| CN202111073775.8 | 2021-09-14 | ||
| CN202111073775 | 2021-09-14 | ||
| CN202111225928 | 2021-10-21 | ||
| CN202111225928.6 | 2021-10-21 | ||
| PCT/CN2022/100016 WO2022268051A1 (zh) | 2021-06-21 | 2022-06-21 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3220929A1 true CA3220929A1 (en) | 2022-12-29 |
Family
ID=84544976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3220929A Pending CA3220929A1 (en) | 2021-06-21 | 2022-06-21 | Fused tetracyclic compound, preparation method therefor and application thereof in medicine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240327434A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4361157A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024522766A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240024903A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117255793B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022297474A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024646A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3220929A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023015533A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202317587A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022268051A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116867792A (zh) * | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| CN117043167A (zh) | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| CN115557974A (zh) * | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN118019746A (zh) * | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
| JP2025504041A (ja) * | 2022-01-30 | 2025-02-06 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | キノリン系化合物及びその使用 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| CN119365467A (zh) * | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| KR20250034087A (ko) * | 2022-07-09 | 2025-03-10 | 블로썸힐 테라퓨틱스, 인크. | 질병 치료를 위한 융합 고리 kras 억제제 |
| TW202409051A (zh) * | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| KR20250037564A (ko) * | 2022-07-29 | 2025-03-17 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Kras g12d 억제제를 포함하는 약학적 조성물 |
| CN119585278A (zh) * | 2022-08-05 | 2025-03-07 | 杭州中美华东制药有限公司 | 具有KRas G12D抑制作用的化合物 |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| TW202426459A (zh) * | 2022-09-23 | 2024-07-01 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| TW202440594A (zh) * | 2022-12-07 | 2024-10-16 | 大陸商北京加科思新藥研發有限公司 | 稠環化合物及其用途 |
| TW202430184A (zh) * | 2022-12-20 | 2024-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Kras g12d抑制劑的結晶形式及製備方法 |
| WO2024149214A1 (en) * | 2023-01-10 | 2024-07-18 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
| WO2024159471A1 (en) * | 2023-02-02 | 2024-08-08 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| WO2024234360A1 (en) * | 2023-05-18 | 2024-11-21 | Nikang Therapeutics , Inc. | Tetracyclic derivatives as kras inhibitors |
| EP4680609A1 (en) | 2023-03-15 | 2026-01-21 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| WO2024208305A1 (zh) * | 2023-04-07 | 2024-10-10 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
| WO2024213979A1 (en) * | 2023-04-10 | 2024-10-17 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024218686A1 (en) * | 2023-04-20 | 2024-10-24 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| JP2026522894A (ja) * | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | Kras調節化合物 |
| JP2026523268A (ja) | 2023-07-13 | 2026-07-13 | 上海森▲輝▼医▲葯▼有限公司 | Kras g12d中間体の調製方法 |
| CN121843945A (zh) * | 2023-07-18 | 2026-04-10 | 泰励生物科技(上海)有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| WO2025045141A1 (en) * | 2023-08-31 | 2025-03-06 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| KR20260110993A (ko) | 2023-10-09 | 2026-07-14 | 인사이트 코포레이션 | Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| CN122228262A (zh) * | 2023-11-02 | 2026-06-16 | 金橘生物科技公司 | 降解剂及其用途 |
| WO2025108443A2 (en) * | 2023-11-23 | 2025-05-30 | Beigene Switzerland Gmbh | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025146194A1 (en) * | 2024-01-05 | 2025-07-10 | Jacobio Pharmaceuticals Co., Ltd. | Fused tetracyclic compounds and use thereof |
| AU2025209726A1 (en) * | 2024-01-17 | 2026-07-09 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| CN119684315B (zh) * | 2024-01-26 | 2026-05-12 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的结晶形式及其制备方法 |
| WO2025157261A1 (zh) * | 2024-01-26 | 2025-07-31 | 江苏恒瑞医药股份有限公司 | G12d抑制剂化合物晶型及其制备方法 |
| CN119490512B (zh) * | 2024-01-26 | 2026-06-16 | 苏州盛迪亚生物医药有限公司 | 一种苯并噻吩取代稠环化合物的可药用盐、其结晶形式及用途 |
| CN119661555B (zh) * | 2024-01-26 | 2026-04-14 | 苏州盛迪亚生物医药有限公司 | 一种稠环类化合物的可药用盐、其结晶形式及用途 |
| US20260137674A1 (en) | 2024-10-23 | 2026-05-21 | Incyte Corporation | Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor |
| WO2026090333A1 (en) | 2024-10-23 | 2026-04-30 | Incyte Corporation | Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2018206539A1 (en) | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| CN110869358A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | Kras的共价抑制剂 |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN113874374B (zh) | 2019-05-24 | 2024-12-27 | 江苏恒瑞医药股份有限公司 | 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| WO2021000885A1 (zh) | 2019-07-01 | 2021-01-07 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| CN114615981B (zh) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| CN116867792A (zh) * | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CN117043167A (zh) * | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| CN115557974A (zh) * | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| WO2023025116A1 (zh) * | 2021-08-25 | 2023-03-02 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| WO2023103906A1 (zh) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| JP2025504041A (ja) * | 2022-01-30 | 2025-02-06 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | キノリン系化合物及びその使用 |
| EP4511127A1 (en) * | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN119365467A (zh) * | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
-
2022
- 2022-06-21 MX MX2023015533A patent/MX2023015533A/es unknown
- 2022-06-21 EP EP22827544.2A patent/EP4361157A4/en active Pending
- 2022-06-21 TW TW111123050A patent/TW202317587A/zh unknown
- 2022-06-21 CA CA3220929A patent/CA3220929A1/en active Pending
- 2022-06-21 BR BR112023024646A patent/BR112023024646A2/pt unknown
- 2022-06-21 AU AU2022297474A patent/AU2022297474A1/en active Pending
- 2022-06-21 JP JP2023577689A patent/JP2024522766A/ja active Pending
- 2022-06-21 WO PCT/CN2022/100016 patent/WO2022268051A1/zh not_active Ceased
- 2022-06-21 US US18/571,909 patent/US20240327434A1/en active Pending
- 2022-06-21 KR KR1020247000906A patent/KR20240024903A/ko active Pending
- 2022-06-21 CN CN202280030759.7A patent/CN117255793B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4361157A4 (en) | 2024-10-16 |
| MX2023015533A (es) | 2024-01-23 |
| KR20240024903A (ko) | 2024-02-26 |
| EP4361157A1 (en) | 2024-05-01 |
| TW202317587A (zh) | 2023-05-01 |
| WO2022268051A1 (zh) | 2022-12-29 |
| CN117255793B (zh) | 2026-06-12 |
| BR112023024646A2 (pt) | 2024-03-05 |
| US20240327434A1 (en) | 2024-10-03 |
| JP2024522766A (ja) | 2024-06-21 |
| AU2022297474A1 (en) | 2024-01-18 |
| CN117255793A (zh) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022297474A1 (en) | Fused tetracyclic compound, preparation method therefor and application thereof in medicine | |
| US12281127B2 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| EP4563580A1 (en) | Fused ring compound, preparation method therefor and medicinal application thereof | |
| CA3210224A1 (en) | Cdk inhibitors and methods of use thereof | |
| ES2857251T3 (es) | Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton | |
| CN117486901A (zh) | 稠合哌啶类化合物、其制备方法及其在医药上的应用 | |
| EP4695262A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| TW202409047A (zh) | 吡啶并[4,3-d]嘧啶化合物 | |
| ES2896943T3 (es) | Compuesto de amino pirazolopirimidina usado como inhibidor de receptores con actividad tirosina quinasa de factores neurotróficos | |
| CA3224284A1 (en) | Kras g12d inhibitor and use thereof | |
| CA3120791A1 (en) | Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof | |
| CA3180615A1 (en) | Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof | |
| CN112824410A (zh) | 氮杂七元环类抑制剂及其制备方法和应用 | |
| UA119229C2 (uk) | Циклічні ефіри піразол-4-ілгетероциклілкарбоксамідних сполук та способи їх застосування | |
| CA3232764A1 (en) | Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereof | |
| KR20240012437A (ko) | 질소 함유 헤테로사이클릭 화합물, 이의 제조 방법 및 의학에서 이의 응용 | |
| CA3159376A1 (en) | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof | |
| CN120365289A (zh) | 稠环类化合物、其制备方法及其在医药上的应用 | |
| AU2021314401A1 (en) | Sulfur-containing isoindoline derivative, and preparation method therefor and medical use thereof | |
| CN114907349A (zh) | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 | |
| JP6554480B2 (ja) | オキセパン−2−イル−ピラゾール−4−イル−ヘテロシクリル−カルボキサミド化合物と使用方法 | |
| CN117659049A (zh) | 取代桥环类抑制剂及其制备方法和应用 | |
| CN113912608A (zh) | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 | |
| JP2026059772A (ja) | ピリド[4,3-d]ピリミジン化合物 | |
| KR20260044145A (ko) | 피리도[4,3-d]피리미딘 화합물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250526 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250526 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260526 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260526 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260610 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260610 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260715 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260715 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260715 |